Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02733263 · ClinicalTrials.gov registry record · NA
Resistant Maltodextrin Supplementation: Gastrointestinal Health
A NA study, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
NCT02733263 is a NA study that has completed, run by University of Florida. The registered enrollment target is 64 participants.
The verdict
NCT02733263, a NA study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
Study Summary
Resistant maltodextrin (RMD) is an indigestible water soluble fiber that increases fecal bulk by enhancing growth of specific microbial populations; however the effect of RMD on bifidobacteria and total fecal weight is not clear. The purpose of this research study is to determine whether incorporating about ¼ cup of a fiber supplement into the diet will induce beneficial changes in gastrointestinal function, the fecal microbiota profile (increased number of healthy bacteria in stool) and immune processes resulting in improved quality of life.
Interventions
- DIETARY_SUPPLEMENT 15 g RMD
- DIETARY_SUPPLEMENT 25 g RMD
- DIETARY_SUPPLEMENT 0 g RMD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2016-05 |
| Est. Completion | 2016-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02733263
The ClinicalTrials.gov registry entry for NCT02733263 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 15 g RMD is the first listed.
NCT02733263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02733263 about?
NCT02733263 is a clinical study titled "Resistant Maltodextrin Supplementation: Gastrointestinal Health". Resistant maltodextrin (RMD) is an indigestible water soluble fiber that increases fecal bulk by enhancing growth of specific microbial populations; however the effect of RMD on bifidobacteria and total fecal weight is not clear. The purpose of this research study is to determine whether incorporati...
What is the current status of trial NCT02733263?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2016-05. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02733263?
The interventions under investigation include: 15 g RMD (DIETARY_SUPPLEMENT), 25 g RMD (DIETARY_SUPPLEMENT), 0 g RMD (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02733263?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.